Graft Failure after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1 SUPPL., 2008, Pages 165-170

  Mattsson, Jonas ^a   Ringdén, Olle ^a   Storb, Rainer ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cord blood transplant; Graft failure; Major histocompatibility complex; Reduced intensity conditioning; Rejection

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; OKT 3; PROTEIN ANTIBODY; THYMOCYTE ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW APLASIA; CHRONIC MYELOID LEUKEMIA; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA; NATURAL KILLER CELL; PLASMAPHERESIS; REDUCED INTENSITY CONDITIONING; RISK FACTOR; T LYMPHOCYTE; THALASSEMIA MAJOR;

CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 37348999625     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.10.025     Document Type: Article

References (63)

1. Cudkowicz G., and Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med 134 (1971) 83-102
2. Kiessling R., Hochman P.S., Haller O., Shearer G.M., Wigzell H., and Cudkowicz G. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol 7 (1977) 655-663
3. Murphy W.J., Kumar V., and Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 166 (1987) 1499-1509
4. Raff R.F., Deeg H.J., Loughran Jr. T.P., et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood 68 (1986) 861-868
5. Raff R.F., Sandmaier B.M., Graham T., Loughran Jr. T.P., Pettinger M., and Storb R. "Resistance" to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 22 (1994) 893-897
6. Deeg H.J., Sale G.E., Storb R., et al. Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate. Transplantation 44 (1987) 340-345
7. Barge A.J., Johnson G., Witherspoon R., and Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 74 (1989) 1477-1480
8. Moeller E. Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 147 (1965) 873-879
9. Warren R.P., Storb R., Weiden P.L., Su P.J., and Thomas E.D. Lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity in patients with aplastic anemia: distinguishing transfusion-induced sensitization from possible immune-mediated aplastic anemia. Transplant Proc 13 (1981) 245-247
10. Taylor P.A., Ehrhardt M.J., Roforth M.M., et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 109 (2007) 1307-1315
11. Storb R., Floersheim G.L., Weiden P.L., et al. Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 112 (1974) 1508-1516
12. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985) 765-771
13. Petersdorf E.W., Hansen J.A., Martin P.J., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345 (2001) 1794-1800
14. Champlin R.E., Horowitz M.M., van Bekkum D.W., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 73 (1989) 606-613
15. Storb R., Prentice R.L., Thomas E.D., et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 55 (1983) 573-585
16. Storb R., Prentice R.L., and Thomas E.D. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 296 (1977) 61-66
17. Storb R., Weiden P.L., Deeg H.J., et al. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood 54 (1979) 477-484
18. Bean M.A., Graham T., Appelbaum F.R., et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation 57 (1994) 423-426
19. Bean M.A., Storb R., Graham T., et al. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation 52 (1991) 956-960
20. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
21. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
22. McSweeney P.A., and Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 5 (1999) 192-203
23. Le Blanc K., Remberger M., Uzunel M., Mattsson J., Barkholt L., and Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 78 (2004) 1014-1020
24. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
25. Deeg H.J., Storb R., Weiden P.L., et al. Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes. Blood 53 (1979) 552-557
26. Storb R., Epstein R.B., Bryant J., Ragde H., and Thomas E.D. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 6 (1968) 587-593
27. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337 (1997) 373-381
28. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88 (1996) 795-802
29. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001) 2962-2971
30. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
31. Remberger M., Watz E., Ringden O., Mattsson J., Shanwell A., and Wikman A. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13 (2007) 675-682
32. Mielcarek M., Leisenring W., Torok-Storb B., and Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 96 (2000) 1150-1156
33. Sumitran-Karuppan S., Tyden G., Reinholt F., Berg U., and Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 5 (1997) 321-327
34. Terasaki P.I., and Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 17 (2005) 541-545
35. Ottinger H.D., Rebmann V., Pfeiffer K.A., et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 73 (2002) 1280-1285
36. Pelosi E., Valtieri M., Coppola S., et al. Identification of the hemangioblast in postnatal life. Blood 100 (2002) 3203-3208
37. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
38. Nordlander A, Mattsson J, Sundberg B, Sumitran-Holgersson S. Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after haematopoietic stem cell transplantation. Submitted.
39. Lion T. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 134 (2007) 197-216
40. McCann S.R., and Lawler M. Mixed chimaerism; detection and significance following BMT. Bone Marrow Transplant 11 (1993) 91-94
41. Zetterquist H., Mattsson J., Uzunel M., et al. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 25 (2000) 843-851
42. Dubovsky J., Daxberger H., Fritsch G., et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 13 (1999) 2059-2060
43. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
44. Mackinnon S., Barnett L., Bourhis J.H., Black P., Heller G., and O'Reilly R.J. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 80 (1992) 3235-3241
45. Mattsson J., Uzunel M., Brune M., et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 115 (2001) 935-944
46. Gluckman E. Report of the European bone marrow transplantation-Aplastic Anemia Working Party. Exp. Hematol 11 13 (1983) 45-47
47. Sodani P., Gaziev D., Polchi P., et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 104 (2004) 1201-1203
48. Bensinger W.I., Weaver C.H., Appelbaum F.R., et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85 (1995) 1655-1658
49. Storb R., Doney K.C., Thomas E.D., et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 59 (1982) 236-246
50. Dreger P., Haferlach T., Eckstein V., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87 (1994) 609-613
51. Storb R., Blume K.G., O'Donnell M.R., et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 7 (2001) 39-44
52. Kahl C., Leisenring W., Deeg H.J., et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 130 (2005) 747-751
53. Carlens S., Remberger M., Aschan J., and Ringden O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 7 (2001) 31-38
54. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
55. Ringden O., Soderdahl G., Mattsson J., et al. Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation 69 (2000) 2043-2048
56. Stucki A., Leisenring W., Sandmaier B.M., Sanders J., Anasetti C., and Storb R. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 92 (1998) 2742-2749
57. Bolger G.B., Sullivan K.M., Storb R., et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1 (1986) 21-30
58. Davies S.M., Weisdorf D.J., Haake R.J., et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 14 (1994) 73-77
59. Remberger M., Ringden O., Ljungman P., et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 22 (1998) 73-78
60. Larocca A., Piaggio G., Podesta M., et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91 (2006) 935-940
61. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21 (2007) 1733-1738
62. Glotz D., Haymann J.P., Sansonetti N., et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 56 (1993) 335-337
63. Tyden G., Kumlien G., and Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76 (2003) 730-731